Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Giudice, E.
Right arrow Articles by Papoian, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giudice, E.
Right arrow Articles by Papoian, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 9, No. 12, pp. 2291-2299, 1994
© 1994 European Society of Human Reproduction and Embryology

research-article

Infertility: Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins

E. Giudice, C. Crisci, A. Eshkol2 and R. Papoian1

2Ares Services Geneva, Switzerland Istituto di Ricerca ‘Cesare Serono’, Via di Valle Caia 22 00040 Ardea (RM) Italy

Correspondence: 1To whom correspondence should be addressed

Gonadotrophin preparations extracted from post-menopausal urine are of low purity and the major protein components are not gonadotrophins. A study was undertaken to identify some of these non-gonadotrophin proteins present in the extracted human urinary gonadotrophin preparations that are commercially available, i.e. Humegon (Organon), HMG Massone (Massone), Metrodin (Serono), Metrodin HP (Serono), Pergonal (Serono) and Progonadyl (Elea). As revealed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie blue staining and Western blotting analysis, these products had electrophoretic protein profiles which differed in the amounts and species of proteins present. With the exception of Metrodin HP, all the other preparations tested contained tumour necrosis factor binding protein-I, transferrin, and immunoglobulin-related proteins. Some of the products contained in addition: urokinase, Tamm-Horsfall glyco-protein and epidermal growth factor. Recently, a highly purified human urinary follicle stimulating hormone (FSH) preparation (Metrodin HP) became available. In this preparation human FSH represents >95% of the total proteins ({approx} 10 000 IU of FSH/mg of protein). Metrodin HP was demonstrated to be the purest preparation tested, with none of the above-mentioned contaminants detected.

Key words: characterization/FSH/infertility/SDS-PAGE/urine-derived gonadotrophins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
F.-J. Huang, K.-C. Lan, F.-T. Kung, M.-Y. Tsai, C.-Y. Chang, H.-W. Huang, Y.-C. Lin, and S.-Y. Chang
Human cumulus-free oocyte maturational profile and in vitro developmental potential after stimulation with recombinant versus urinary FSH
Hum. Reprod., February 1, 2004; 19(2): 306 - 315.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E. H. Y. Ng, E. Y. L. Lau, W. S. B. Yeung, and P. C. Ho
HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial
Hum. Reprod., February 1, 2001; 16(2): 319 - 325.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. E. R. H. L. S. Group
Recombinant Human Luteinizing Hormone (LH) to Support Recombinant Human Follicle-Stimulating Hormone (FSH)-Induced Follicular Development in LH- and FSH-Deficient Anovulatory Women: A Dose-Finding Study
J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1507 - 1514.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
B. C. J. M. Fauser and A. M. van Heusden
Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences
Endocr. Rev., February 1, 1997; 18(1): 71 - 106.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.